Cargando…

Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements

BACKGROUND: An extensive body of research reveals the clinical value of serum tumor markers in lung cancer patients, including carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), cytokeratin-19 fragments (Cyfra21-1), and neuron-specific enolase (NSE), but little is known about th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shouying, Cao, Lianjing, Wang, Xinyue, Wang, Fan, Wang, Liuchun, Jiang, Richeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353286/ https://www.ncbi.nlm.nih.gov/pubmed/30673691 http://dx.doi.org/10.12659/MSM.913054

Ejemplares similares

PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level
por: Cao, Lianjing, et al.
Publicado: (2017)

Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer
por: Wang, Xinyue, et al.
Publicado: (2019)

Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement
por: Shukla, Saumya, et al.
Publicado: (2019)

Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers
por: Ma, De-Ning, et al.
Publicado: (2020)

Metastatic Anaplastic Lymphoma Kinase Rearrangement-Positive Adenocarcinoma of Occult Primary Mimicking Ovarian Cancer
por: Chahin, Michael, et al.
Publicado: (2020)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
por: Lee, Jeeyun, et al.
Publicado: (2015)

Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
por: Katayama, Ryohei
Publicado: (2018)

Control of brain metastases with alectinib in anaplastic lymphoma kinase‐rearranged lung cancer
por: Kwok, Wang Chun, et al.
Publicado: (2017)

Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma
por: Yang, Sen, et al.
Publicado: (2020)

Pulmonary Spindle Cell Carcinoma Presenting Anaplastic Lymphoma Kinase Rearrangement
por: Sonehara, Kei, et al.
Publicado: (2023)

Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung
por: Shi, Mingxia, et al.
Publicado: (2018)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers [Corrigendum]
Publicado: (2023)

Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma
por: Zhu, Pei, et al.
Publicado: (2015)

Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase‐positive and surgically resected lung adenocarcinoma
por: Tao, Hong, et al.
Publicado: (2016)

Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement
por: AKIBA, JUN, et al.
Publicado: (2014)

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
por: Zhou, Jianya, et al.
Publicado: (2015)

Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment Implications
por: Hainsworth, John D., et al.
Publicado: (2016)

Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population
por: Ying, Jianming, et al.
Publicado: (2015)

Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report
por: SUN, QIONG, et al.
Publicado: (2014)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2020)

Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan
por: Maraqa, Bayan, et al.
Publicado: (2022)

Clinical significance of serum neuron-specific enolase in gastric adenocarcinoma
por: Luo, Hai, et al.
Publicado: (2020)

Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study
por: Zhong, Wei-Xiang, et al.
Publicado: (2022)

Spatially Resolved Proteomic and Transcriptomic Profiling of Anaplastic Lymphoma Kinase-Rearranged Pulmonary Adenocarcinomas Reveals Key Players in Inter- and Intratumoral Heterogeneity
por: Szeitz, Beáta, et al.
Publicado: (2023)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
por: Hayashi, Nobuyoshi, et al.
Publicado: (2017)

Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Fukui, Takafumi, et al.
Publicado: (2022)

Correction to: Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Destaining of Diff-Quik stained cytologic smears is not necessary for the detection of anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma by fluorescence in situ hybridization
por: Xu, Weisheng, et al.
Publicado: (2016)

Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment
por: Rosoux, Adeline, et al.
Publicado: (2017)

A primary retroperitoneal anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor thrombosis
por: Li, Jisong, et al.
Publicado: (2018)

Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population
por: Lopes, Lisandro F, et al.
Publicado: (2012)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
por: Kitadai, Rui, et al.
Publicado: (2018)

Aggressive Inflammatory Myofibroblastic Tumor without Anaplastic Lymphoma Kinase Gene Rearrangement in the Rectum with Liver Metastasis
por: Shimodaira, Yosuke, et al.
Publicado: (2019)

Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy
por: Sasaki, Takaaki, et al.
Publicado: (2023)

Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma
por: Tian, Chen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ckp07j2f18m6j890audt6logqb